BeOne Medicines boosts third-quarter revenue from key drugs
BeOne Medicines Ltd. reported third-quarter 2026 financial results, with global sales of BRUKINSA reaching $1.4 billion and free cash flow of $474 million. For shareholders, this signals strengthened financials driven by core oncology product sales, allowing the company to revise its annual guidance.
Key points
- For the quarter ended September 30, 2026, global BRUKINSA sales rose 34% to $1.4 billion, with $1.0 billion from the U.S. market.
- The company decided to stop promoting POBEVCY, leading to a $22 million impairment charge on intangible assets.
Quarterly financial results
For the quarter ended September 30, 2026, global BRUKINSA sales rose 34% to $1.4 billion, with $1.0 billion from the U.S. market. TEVIMBRA sales reached $243 million, a 28% increase. Net income for the third quarter hit $385 million, and free cash flow was $474 million.
Key financial indicators (Q3 2026)
Revenue by quarter, $B
Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.
Portfolio adjustments and management decisions
The company decided to stop promoting POBEVCY, leading to a $22 million impairment charge on intangible assets. This move aims to optimize expenses and refocus strategic priorities.
On October 27, 2026, director Wang Xiaodong sold 31,028 company shares. The transaction followed a pre-approved Rule 10b5-1 trading plan—a preset selling schedule executives set up in advance that allows insiders to sell shares without affecting the confidentiality of current strategic information.
What to watch
Shareholders should look to the annual report for final 2026 revenue and operating income figures. That report will evaluate whether the company met the updated financial guidance issued after the third quarter.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow BeOne Medicines
A notification in your browser or on your phone when we publish about BeOne Medicines. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
